In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

leading scientists to identify a potential precision medicine approach to prevent chronic kidney disease progression. Novo Nordisk today presented the full results from the SOUL cardiovascular ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

In a large study of diabetes, heart failure, or chronic kidney disease patients on renin-angiotensin-aldosterone system (RAAS ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Longer-term data will show whether semaglutide can prevent liver transplants or death from liver disease, Khungar said. Novo Nordisk is continuing to monitor trial participants to see how their ...

executive vice president of Product & Portfolio Strategy at Novo Nordisk. "Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and ...